5.5
Hold
Average of 2 AIs
→ Unchanged from previous
Last Updated: 5 Mar 2026, 09:37 pm IST | Report Date: Feb 14, 2026

Vineet Laboratories Limited Stock Analysis

VINEETLAB NSE 🇮🇳 India
5.5
ChatGPT
Hold
5.5
Claude
Hold

Vineet Laboratories Limited (VINEETLAB) is a India-based company listed on NSE. This AI-powered analysis provides investment insights based on quarterly earnings reports and financial performance metrics.

Share Share Share

Overall verdict: hold, because Vineet Laboratories shows an early earnings recovery but still carries balance-sheet and margin stress. In Q3 FY2025-26, revenue from operations fell 13.54% YoY to INR 1,564.83 lakh, yet the company swung to PAT of INR 85.07 lakh (EPS INR 0.92) from a loss of INR 570.70 lakh last year. Profit quality is mixed, as PBT was INR 81.80 lakh and PAT was lifted by a negative tax expense of INR 3.27 lakh, while finance costs stayed high at INR 109.46 lakh and interest coverage remained weak at 0.75. EBITDA margin was 9.2%, operating margin 5.21%, and net margin 5.44%, indicating only modest underlying profitability. Nine-month PAT of INR 38.56 lakh also suggests recovery is still fragile rather than fully established.

Based on: Vineet Laboratories Limited - Financial Results (14/2/2026) (Feb 14, 2026)

AI Investment Score & Analysis

+ Key Strengths

The company returned to profitability in Q3 FY2025-26 with PAT of INR 85.07 lakh versus a loss of INR 570.70 lakh in Q3 FY2024-25.
EPS improved to INR 0.92 in Q3 FY2025-26 from INR -6.19 in the prior-year quarter.
Operating performance was positive with EBITDA of INR 144.34 lakh and an EBITDA margin of 9.2%.
Inventory movement improved sequentially, with destocking of INR 6.43 lakh in Q3 versus a large build-up of INR 527.33 lakh in Q2.
Strategic capacity build-out is underway, with approved installations of Quality Control and Purified RO Water equipment at a new production facility.

- Key Risks

Revenue momentum is weak, with revenue from operations down 13.54% YoY to INR 1,564.83 lakh.
Finance costs remain heavy at INR 109.46 lakh, materially constraining profitability.
Interest coverage of 0.75 indicates weak debt-servicing headroom and elevated financial risk.
Cost structure is still tight, as cost of materials consumed 62.08% of revenue (INR 971.66 lakh), limiting margin expansion.
Profit quality is not fully robust because PAT (INR 85.07 lakh) exceeded PBT (INR 81.80 lakh) due to a negative tax expense of INR 3.27 lakh, and disclosures note Rights Issue proceeds being used for equipment not originally mentioned in the December 17, 2025 Letter of Offer.

Forward Outlook

During Q3, management advanced and ratified payments for Quality Control and Purified RO Water equipment at a new production facility, signaling a clear capacity expansion initiative in the API/intermediates business. Over the next 2-4 quarters, key catalysts are commissioning and ramp-up of this facility, and whether higher scale can absorb fixed costs and improve margins from current levels (EBITDA margin 9.2%, operating margin 5.21%). Momentum is mixed: profitability has improved sharply and revenue appears sequentially stable versus Q2, but YoY sales are still contracting (-13.54%), so growth is not yet broad-based. Additional watchpoints for the next 6-12 months are finance-cost burden (INR 109.46 lakh in Q3) and any cost impact once New Labour Codes implementation details are finalized.

Detailed AI Analysis by Provider

5.5
OpenAI ChatGPT Hold
codex-cli (OpenAI Codex)

Overall verdict: hold, because Vineet Laboratories shows an early earnings recovery but still carries balance-sheet and margin stress. In Q3 FY2025-26, revenue from operations fell 13.54% YoY to INR 1,564.83 lakh, yet the company swung to PAT of INR 85.07 lakh (EPS INR 0.92) from a loss of INR 570.70 lakh last year. Profit quality is mixed, as PBT was INR 81.80 lakh and PAT was lifted by a negative tax expense of INR 3.27 lakh, while finance costs stayed high at INR 109.46 lakh and interest coverage remained weak at 0.75. EBITDA margin was 9.2%, operating margin 5.21%, and net margin 5.44%, indicating only modest underlying profitability. Nine-month PAT of INR 38.56 lakh also suggests recovery is still fragile rather than fully established.

Forward Outlook

During Q3, management advanced and ratified payments for Quality Control and Purified RO Water equipment at a new production facility, signaling a clear capacity expansion initiative in the API/intermediates business. Over the next 2-4 quarters, key catalysts are commissioning and ramp-up of this facility, and whether higher scale can absorb fixed costs and improve margins from current levels (EBITDA margin 9.2%, operating margin 5.21%). Momentum is mixed: profitability has improved sharply and revenue appears sequentially stable versus Q2, but YoY sales are still contracting (-13.54%), so growth is not yet broad-based. Additional watchpoints for the next 6-12 months are finance-cost burden (INR 109.46 lakh in Q3) and any cost impact once New Labour Codes implementation details are finalized.

Strengths

The company returned to profitability in Q3 FY2025-26 with PAT of INR 85.07 lakh versus a loss of INR 570.70 lakh in Q3 FY2024-25.
EPS improved to INR 0.92 in Q3 FY2025-26 from INR -6.19 in the prior-year quarter.
Operating performance was positive with EBITDA of INR 144.34 lakh and an EBITDA margin of 9.2%.
Inventory movement improved sequentially, with destocking of INR 6.43 lakh in Q3 versus a large build-up of INR 527.33 lakh in Q2.
Strategic capacity build-out is underway, with approved installations of Quality Control and Purified RO Water equipment at a new production facility.

Risks

Revenue momentum is weak, with revenue from operations down 13.54% YoY to INR 1,564.83 lakh.
Finance costs remain heavy at INR 109.46 lakh, materially constraining profitability.
Interest coverage of 0.75 indicates weak debt-servicing headroom and elevated financial risk.
Cost structure is still tight, as cost of materials consumed 62.08% of revenue (INR 971.66 lakh), limiting margin expansion.
Profit quality is not fully robust because PAT (INR 85.07 lakh) exceeded PBT (INR 81.80 lakh) due to a negative tax expense of INR 3.27 lakh, and disclosures note Rights Issue proceeds being used for equipment not originally mentioned in the December 17, 2025 Letter of Offer.
5.5
Anthropic Claude Hold
claude-cli (Claude Code)

Vineet Laboratories shows a tactical turnaround in Q3 FY2025-26 with return to profitability (PAT of INR 85.07 lakh vs loss of INR 570.70 lakh YoY), but this improvement masks structural concerns. Revenue declined 13.54% YoY to INR 1564.83 lakh while material costs remain elevated at 62.08% of revenue, compressing gross margins to 37.9%. The interest coverage ratio of 0.75x signals distressed debt servicing capacity, with finance costs of INR 109.46 lakh nearly consuming the entire operating profit of INR 81.80 lakh. Net profit margin of 5.44% and operating margin of 5.21% remain thin, and the company utilized Rights Issue proceeds for equipment purchases not disclosed in the original Letter of Offer, raising governance questions. While the profit swing is encouraging, weak top-line growth, sub-1x interest coverage, and minimal operating leverage suggest cautious positioning is warranted.

Forward Outlook

The company is investing in production infrastructure with Quality Control and Purified RO Water equipment at a new production facility, indicating expectations for volume growth in coming quarters once capacity comes online. However, no specific timelines, revenue targets, or product pipeline details were disclosed in the Q3 report. The destocking trend in Q3 (INR 6.43 lakh reduction vs INR 527.33 lakh build-up in Q2) suggests the company may be preparing for fresh production cycles, but revenue visibility remains unclear given the 13.54% YoY decline. Management will evaluate financial impacts from New Labour Codes implementation once finalized, which could affect cost structure in FY2026-27. Near-term catalysts depend on revenue stabilization and operating leverage from the new capacity, but the sub-1x interest coverage ratio constrains financial flexibility until debt servicing improves materially.

Strengths

Returned to quarterly profitability with PAT of INR 85.07 lakh (EPS 0.92) in Q3 FY2025-26 after four consecutive quarters of losses including a INR 570.70 lakh loss in Q3 FY2024-25
Inventory destocking of INR 6.43 lakh in Q3 versus significant build-up of INR 527.33 lakh in Q2 indicates improved working capital management
EBITDA margin improved to 9.2% with EBITDA of INR 144.34 lakh, providing some operating cushion despite revenue headwinds
Investing in production capacity expansion with new Quality Control and Purified RO Water equipment installations at new production facility, signaling growth preparation
Nine-month cumulative performance shows positive PAT of INR 38.56 lakh on revenue of INR 4050.96 lakh, indicating the loss-making phase may be reversing

Risks

Interest coverage ratio of just 0.75x demonstrates inability to service debt from operating profits, with finance costs of INR 109.46 lakh exceeding EBIT of INR 81.80 lakh
Revenue declined 13.54% YoY to INR 1564.83 lakh from INR 1809.93 lakh, indicating market share loss or demand contraction in the API and intermediates segment
Material costs at 62.08% of revenue remain structurally high, limiting pricing power and gross margin expansion despite volume changes
Company approved equipment payments not originally disclosed in the Rights Issue Letter of Offer dated December 17, 2025, raising corporate governance and capital allocation transparency concerns
Deferred tax assets of INR 3.27 lakh suggest accumulated losses or timing differences, and management flagged potential material impact from New Labour Codes 2020 on contract workforce costs
Net profit margin of 5.44% and operating margin of 5.21% remain razor-thin, leaving minimal buffer against cost inflation or revenue shocks

Score History

Score Timeline

Quarterly Report News Event

All Scores

Date Report Score Sentiment AI
Mar 5, 2026 Vineet Laboratories Limited - Financial Results (14/2/2026) 5.5 Hold ChatGPT
Feb 28, 2026 Vineet Laboratories Limited - Financial Results (14/2/2026) 5.5 Hold Claude

Related Stocks on NSE

Reliance Industries
RELIANCE
7.5
Soma Textiles & Industries Limited
SOMATEX
5.8
Stylam Industries Limited
STYLAMIND
5.0
Melstar Information Technologies Limited
MELSTAR
2.0
Ice Make Refrigeration Limited
ICEMAKE
5.5
Signet Industries Limited
SIGIND
5.2
Vipul Limited
VIPULLTD
Moksh Ornaments Limited
MOKSH
4.0

Frequently Asked Questions

What is the AI Stock Score?

The AI Stock Score is a composite rating from 0-10 generated by analyzing quarterly earnings reports using three leading AI models (Google Gemini, Anthropic Claude, and OpenAI ChatGPT). Each AI independently evaluates financial performance, growth prospects, risks, and market positioning to provide an objective investment perspective.

How should I interpret Buy/Hold/Sell ratings?

Buy (7.0-10.0): Strong fundamentals and positive outlook. Hold (4.0-6.9): Mixed signals, suitable for existing positions. Sell (0-3.9): Deteriorating fundamentals or significant risks. These are AI-generated opinions for informational purposes only, not investment advice.

How is the composite score calculated?

The composite score is the mathematical average of the latest scores from each AI provider. For example, if Gemini rates 7.5, Claude rates 4.5, and ChatGPT rates 6.0, the composite score would be (7.5+4.5+6.0)/3 = 6.0. This multi-AI approach reduces bias from any single model.

How often are scores updated?

Scores are automatically generated within hours of quarterly earnings results being published on NSE. The system monitors earnings announcements 4 times daily and processes new reports immediately. Check the "Last Updated" date at the top of this page for the most recent analysis timestamp.

Is this financial advice?

No. This is AI-generated analysis for informational and educational purposes only. MarketsHost is not a SEBI-registered Research Analyst or Investment Adviser. AI models can produce inaccurate results. Always consult a qualified financial advisor and conduct your own due diligence before making investment decisions.